We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Genome Analysis Study to Aid Diagnosis of Rare Developmental Disorders

By LabMedica International staff writers
Posted on 06 Jan 2015
First results from a study that will eventually incorporate complete genome analysis of 12,000 families in the United Kingdom and the Republic of Ireland have revealed 12 novel genes associated with rare and difficult to diagnose developmental disorders.

The Deciphering Developmental Disorders (DDD) study, which is underwritten primarily by the Wellcome Trust Sanger Institute (Hinxton, United Kingdom) was designed to capitalize on the latest genetic techniques in order to help doctors understand the basis for developmental disorders. More...
The program has brought together clinicians in the 24 Regional Genetics Services throughout the United Kingdom and researchers at the Wellcome Trust Sanger Institute, which played a leading role in sequencing the human genome. The DDD study involves experts in clinical, molecular, and statistical genetics as well as in ethics and social science.

The first paper to be published under the auspices of the DDD program reported results from a study of 1,133 children with severe, undiagnosed developmental disorders, and their parents, using a combination of exome sequencing and array-based detection of chromosomal rearrangements. The investigators reported discovering 12 novel genes associated with developmental disorders. These newly implicated genes increased by 10% (from 28% to 31%) the proportion of children that could be diagnosed. All of the newly diagnosed developmental disorders were caused by de novo mutations, which were present in the child but not in their parents' genomes.

DDD's nationwide secure data-sharing network made it possible to find and compare these rare disorders. For example, for four of the 12 newly identified genes, identical mutations were found in two or more unrelated children living hundreds of miles apart. In another example, two unrelated children, both with identical mutations in the PCGF2 (Polycomb group RING finger protein 2) gene, which is involved in regulating genes important in embryo development, were found to have strikingly similar symptoms and facial features. This discovery enabled the certification of a new, distinct dysmorphic syndrome.

"The DDD study has shown how combining genetic sequencing with more traditional strategies for studying patients with very similar symptoms can enable large-scale gene discovery," said contributing author Dr. John Burn, professor of clinical genetics at Newcastle University (United Kingdom). "This data-set becomes more effective with each diagnosis and each newly identified gene."

The study was published in the December 24, 2014, online edition of the journal Nature.

Related Links:

Wellcome Trust Sanger Institute
Newcastle University



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Neurofilament Light Chain Assay
Lumipulse G NfL Blood
New
Gastrointestinal Panel
Xpert® GI Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: LVOne uses blood-based biomarkers to detect stroke and identify large vessel occlusion before hospital arrival, providing objective results earlier than traditional assessments. (Photo courtesy of UpFront Diagnostics)

First-of-Its-Kind Rapid Blood Test Gains CE Mark to Support Prehospital Stroke Triage

Rapid stroke identification before hospital arrival is critical because treatment efficacy declines with every minute of delay. However, definitive assessment typically requires hospital-based imaging,... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: Ebola remains a rapidly evolving public health threat with high mortality, underscoring the need for timely diagnosis and decentralized testing closer to patients (Image Credit: Adobe Stock)

Collaboration Targets Blood-Based Ebola Detection Outside Central Laboratories

Co-Diagnostics, Inc. (Salt Lake City, UT, USA) and ReadyGo Diagnostics Ltd. (Bath, UK) have initiated a collaboration to evaluate ReadyGo’s GoCollect with the Co-Dx PCR platform for blood-based molecular... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Galleri is designed to detect cancer-specific methylation patterns across multiple cancer types before symptoms appear, including cancers without recommended screening (Photo courtesy of GRAIL)

Multi-Cancer Early Detection Test Wins FDA Panel Backing for Approval

GRAIL’s Galleri multi-cancer early detection (MCED) test was reviewed by the Molecular and Clinical Genetics Devices Panel of the U.S. Food and Drug Administration’s (FDA) Medical Devices Advisory Committee.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.